Dianthus Therapeutics (DNTH) Reiterated at Buy by Stifel
Tweet Send to a Friend
Stifel analyst Alex Thompson reiterated a Buy rating and $120.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).The analyst commented, "Sanofi ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


